Evaluation of Combination Therapy in the Management of Vaginitis
Authors/Creators
- 1. Department of Obstetrics and Gynaecology, Netaji Subhash Chandra Bose Medical College and Hospital Jabalpur, Madhya Pradesh, India
- 2. Department of Obstetrics and Gynaecology, Netaji Subhash Chandra Bose Medical College andHospital Jabalpur, Madhya Pradesh, India
Description
Introduction: The efficacy of vaginitis treatment regimens that combine antimicrobial and antiviral agents was evaluated. Antibiotics plus probiotics or intravaginal pH modulators have shown promise in lowering BV recurrence rates. Recurrent or complex cases of VVC may benefit from a combination of topical corticosteroids and antifungal or antibacterial agents. Vaginitis treatment options include antiseptics, which have also been proposed. Aims and Objectives: This study aims to assess the efficacy of combination therapy in the treatment of vaginitis, considering the varying causes of vaginitis. Methods: Convenience sampling was used to enroll sixty patients with complaints of vaginal discharge from a university gynaecological clinic for this clinical trial. The patients all reported having vaginal discharge. A series of diagnostic evaluations were carried out to diagnose vaginal candidiasis, bacterial vaginosis, or non-specific vaginitis. These evaluations included symptoms, vaginal pH, fungal components, the Whiff test, gynaecological exams, the Amsel criteria, and clue cells. Results: The study has found that the frequency of adverse effects and improvement in symptoms for vulvovaginal candidiasis, bacterial vaginosis, and non-specific vaginitis. All groups experienced considerable improvement in symptoms while on therapy. The study also showed that the typical VAS satisfaction ratings for oral metronidazole and combined treatment. Satisfaction levels were similar, comparing the two approaches to treating bacterial vaginosis and non-specific vaginitis. Conclusion: The study has concluded that combination therapy significantly improved vaginitis than a mono-therapy of metronidazole.
Abstract (English)
Introduction: The efficacy of vaginitis treatment regimens that combine antimicrobial and antiviral agents was evaluated. Antibiotics plus probiotics or intravaginal pH modulators have shown promise in lowering BV recurrence rates. Recurrent or complex cases of VVC may benefit from a combination of topical corticosteroids and antifungal or antibacterial agents. Vaginitis treatment options include antiseptics, which have also been proposed. Aims and Objectives: This study aims to assess the efficacy of combination therapy in the treatment of vaginitis, considering the varying causes of vaginitis. Methods: Convenience sampling was used to enroll sixty patients with complaints of vaginal discharge from a university gynaecological clinic for this clinical trial. The patients all reported having vaginal discharge. A series of diagnostic evaluations were carried out to diagnose vaginal candidiasis, bacterial vaginosis, or non-specific vaginitis. These evaluations included symptoms, vaginal pH, fungal components, the Whiff test, gynaecological exams, the Amsel criteria, and clue cells. Results: The study has found that the frequency of adverse effects and improvement in symptoms for vulvovaginal candidiasis, bacterial vaginosis, and non-specific vaginitis. All groups experienced considerable improvement in symptoms while on therapy. The study also showed that the typical VAS satisfaction ratings for oral metronidazole and combined treatment. Satisfaction levels were similar, comparing the two approaches to treating bacterial vaginosis and non-specific vaginitis. Conclusion: The study has concluded that combination therapy significantly improved vaginitis than a mono-therapy of metronidazole.
Files
IJPCR,Vol15,Issue6,Article128.pdf
Files
(323.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:7aecc49aa9054be5b898cbc5d9f730a4
|
323.0 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-04-23
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue6,Article128.pdf
- Development Status
- Active
References
- 1. Koumans EH, Kendrick JS, Group CBVW. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sexually transmitted diseases. 2001;28(5):292– 7. 2. Simoes J, Discacciati M, Brolazo E, Portugal P, Dini D, Dantas M. Clinical diagnosis of bacterial vaginosis. International Journal of Gynecology & Obstetrics. 2006;94(1):28–32. 3. Moori H, Majd A. The comparison of the effects of micosin vaginal cream (made of garlic) and metronidazole vaginal gel on treatment of bacterial vaginosis. Arak Medical University Journal. 2010;13(3):35–44. 4. Nyirjesy P. Chronic vulvovaginal candidiasis. Am Fam Physician. 2001; 63(4):697–702. 5. Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infectious Disease Clinics. 2008;22(4):637–52. 6. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010: Centers for Disease Control and Prevention; 2010. 7. Tempera G, Furneri P, Carlone N, Cocuzza C, Rigoli R, Musumeci R, et al. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren. Journal of Chemotherapy. 2010;22(3):153–9. 8. Verstraelen H, Verhelst R. Bacterial vaginosis: an update on diagnosis and treatment. Expert review of antiinfective therapy. 2009;7(9):1109–24. 9. Verstraelen H, Verhelst R, Roelens K, Temmerman M. Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review. BMC infectious diseases. 2012 ;002012(1):148. 10. Donders G, Bellen G, Rezeberga D. Aerobic vaginitis in pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology. 2011;118(10):1163– 70. 11. Molteni B, D'Antuono A, Bandini P, Sintini G, Barcellona E, Agnello A, et al. Efficacy and tolerability of a new chlorhexidine-based vaginal gel in vaginal infections. Current medical research and opinion. 2004;20(6):849– 53. 12. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. Journal of controlled release. 2005; 103(2) 0020:301–13. 13. Ceschel G, Maffei P, Borgia SL, Ronchi C, Rossi S. Development of a mucoadhesive dosage form for vaginal administration. Drug development and industrial pharmacy. 2001;27(6):541– 7. 14. Kast CE, Valenta C, Leopold M, Bernkop-Schnürch A. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clotrimazole. Journal of Controlled Release. 2002;81(3):347–54. 15. Abruzzo A, Bigucci F, Cerchiara T, Saladini B, Gallucci M, Cruciani F, et al. Chitosan/alginate complexes for vaginal delivery of chlorhexidine digluconate. Carbohydrate polymers. 2013;91(2):651–8. 16. Mirzaeei S, Zangeneh M, Veisi F, Parsa S, Hematti M. Chlorhexidine,clotrimazole, metronidazole and combination therapy in the treatment of vaginal infections. Journal of Medicine and Life. 2021 Mar;14(2) :250. 17. Bahadoran P, Rokni FK, Fahami F. Investigating the therapeutic effect of vaginal cream containing garlic and thyme compared to clotrimazole cream for the treatment of mycotic vaginitis. Iranian journal of nursing and midwifery research. 2010;15(Suppl1): 343. 18. Mousavi M, Mannani R, Mottaghi M, Torkan B, Afrouzan H. Comparing the effect of propolis vaginal cream and metronidazol vaginal gel for treatment of bacterial vaginosis. ZUMS Journal. 2016;24(106):42–50. 19. Aghamirian M, Keshavarz D, JAHANI HH, SADEGHI GM. Agents associated with candida vulvovaginitis in women referred to health centers in Qazvin. 2007. 20. Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2006;126(1): 121–5. 21. Farahmand M, Abedini M, Hashemi Z. Prevalence of vaginitis in Iranian women--symptoms and clinical association. Medical Science Journal of Islamic Azad Univesity-Tehran Medical Branch. 2012;22(1):62–8. 22. Legal H. The treatment of trichomonas and candida vaginitis with clotrimazole vaginal tablets. Postgraduate medical journal. 1974; 50:81. 23. Moallaie H, Verissimo C, Brandão J, Rosado L. The Sensitivity and Resistance of Yeasts Isolated from Women with Vulvovaginal Candidiasis to Common Antifungal drugs Using Disc Diffusion. Journal of Sabzevar School of Medical Sciences. 2010: 213–9. 24. Banaeian S, Sereshti M, Rafieian M, Farahbod F, Kheiri S. Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial. Journal de mycologie medicale. 2017; 27(4):494–500.